AI Eye: iRhythm (NasdaqGS: $IRTC) Wins NHS Funding Through AI Healthcare Award And BlackBerry’s (NYSE: $BB) QNX Platform To Be Leveraged By StradVision
Seeking Alpha Analyst Since 2010
Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.
We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.
Stock News, podcasts - AI, Biotech, Cannabis, Cleantech, #ESG, #Crypto, Gaming, Mining, Tech, Vegan/wellness, water on TSX, TSXV, CSE, OTC, NASDAQ, NYSE
Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.
#AIEye Episode 427: iRhythm (NasdaqGS: $IRTC) Wins NHS Funding Through #AI Healthcare Award and BlackBerry’s (NYSE: $BB) QNX Platform to be Leveraged by StradVision
AI in Life Sciences Market to Reach $4.893 Billion by 2025
Point Roberts WA, Vancouver BC – September 8, 2020 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence(AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence.
Listen to today’s podcast:
https://www.investorideas.com/Audio/Podcasts/2020/090820-AI-Eye.mp3
Read this in full at AI Eye Episode 427: iRhythm (NasdaqGS: $IRTC) Wins NHS Funding Through AI Healthcare Award and BlackBerry's (NYSE: $BB) QNX Platform to be Leveraged by StradVision
Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence
Stocks discussed: (NasdaqGS:IRTC) (NYSE:BB)
Digital healthcare solutions firm iRhythm Technologies, Inc. (NasdaqGS:IRTC) has won the Artificial Intelligence (AI) in Health and Care Award in a competitive process run by the UK’s NHS AI Lab, by “combining the power of artificial intelligence with the expertise of the NHS to improve health and care outcomes.” The company will consequently receive NHS funding, which it will use to trial its Zio service, described in the press release as “a small, discreet and easy-to-use cardiac monitoring service, used to detect a range of arrhythmias quickly and accurately,” which is underpinned by AI. iRhythm’s GM and VP EMEA, Justin Hall, said:
“The UK is home to some of the most cutting-edge, life-changing medical technologies. However, it is still taking years for medical devices to go from clinical trial to wide-spread adoption, meaning neither patients nor practitioners are seeing the many benefits of these innovations. We’re absolutely delighted to have been chosen as part of the pilot to change that.”
BlackBerry Limited (NYSE:BB) has announced that AI-based camera perception technology leader StradVision has selected its QNX Software Development Platform for utilization within a number of next generation Advanced Driver Assistance Systems (ADAS) and Autonomous Vehicles (AV) from South Korean automakers. Junhwan Kim, CEO, StradVision, commented:
“The competitiveness of SVNet lies in its flexibility with its broad hardware support and deep learning software for the advancement of safer driving. Leveraging BlackBerry technology will reinforce SVNet as one of the most reliable, safe and robust camera perception solutions for ADAS & Autonomous Vehicles, enabling us to bring more innovation and convenience to customers.”
AI in Life Sciences Market to Reach $4.893 Billion by 2025
A report from Mordor Intelligence finds that the global AI in Life Sciences market will grow from $1.101 billion in 2019 to $4.893 billion by 2025 with a compound annual growth rate (OTC:CAGR) of 29.42 percent in the forecast period 2020-2025. An excerpt from the report snapshot outlines the impact of AI being leveraged for clinical trials:
Clinical trial research is an extensive progress, which can be reduced with the help of AI in numerous ways. One is by using advanced predictive analytics on a broad range of data to identify candidates for clinical trials for target populations more quickly. Additionally, machine learning applications can make clinical trials more efficient by facilitating tasks, such as calculating ideal sample sizes, facilitating patient recruitment, and using medical records to minimize data errors.
Sam Mowers, Investorideas.com
Read and hear other editions of the AI Eye
For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member
About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles,podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns :Crypto Corner ,Play by Play sports and stock news column,Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change ,Exploring Mining theAI Eye .
The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.
Visit the Podcast page at Investorideas.com:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: InvestorIdeas - Disclaimer, full disclosure, compensation disclosure Learn more about publishing your news release and our other news services on the Investorideas.com newswire Investorideas.com Stock News, Newswire, press release, social media and ticker tag articles services for TSX stocks, CSE.com stocks, NYSE stocks, NASDAQ stocks, OTC stocks and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: InvestorIdeas.com - Privacy Policy
The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com
Follow us on Twitterhttps://twitter.com/Investorideas
Follow us on FacebookInvestorideas.com -Investing Ideas
Follow us on YouTubeInvestorIdeas.com - news that inspires big ideas
Download ourMobile App for iPhone and Android
Join our Investor ClubJoin Investorideas.com and get investing podcasts and ideas for cannabis, cleantech and climate change, artificial intelligence, crypto and blockchain, vegan, mining, and esports stocks
Contact Investorideas.com
800 665 0411
Get more Technology stock investor ideas - news, articles, podcasts and stock directories
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.